Search Results

MGC Pharmaceuticals Ltd, Rebrands as Argent BioPharma in Strategic Transformation Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.

MGC Pharmaceuticals Ltd., announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Portfolio Expands to Include Non-Invasive Cardiorespiratory Diagnostic Systems CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., will acquire St. Paul, Minnesota-based MGC Diagnostics Holdings, Inc. MGC designs, develops, manufactures, and markets non-invasive cardiorespiratory diagnostic systems, accessories, and consumables for the detection, classification, and management of cardiorespiratory disease.

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

MacroGenics, Inc. (NASDAQ: MGNX) today provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC).

MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH.

MGC Pharmaceuticals Ltd. announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter drug in the USA on the FDA National Drug Code Database under the code 83278.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.